Rodman & Renshaw initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $48 price target The firm says the opportunity arising from the dual-targeting mechanism of ficerafusp and a higher probability for success in PD-L1-positive head and neck cancers provide for the majority of its valuation for the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: